EU: Possible virus drug approval 'before the summer'

Image
AP London
Last Updated : May 14 2020 | 5:41 PM IST

The European Medicines Agency predicted that there could be licensed drugs to treat the new coronavirus in the next few months and that a vaccine might even be approved in early 2021, in a best-case scenario.

Dr Marco Cavaleri, who heads the European regulator's vaccines department, told a media briefing on Thursday that approving medicines to treat COVID-19 might be possible before the summer, citing ongoing clinical trials. Recent early results for the drug remdesivir suggested it could help patients recover from the coronavirus faster, although longer-term data is still needed to confirm any benefit.

Although it typically takes years to develop a vaccine, Cavaleri said that if some of the shots already being tested prove to be effective, they could be licensed as early as the beginning of next year.

Cavaleri cautioned, however, that many experimental vaccines never make it to the end and that there are often delays.

But we can see the possibility that if everything goes as planned, vaccines could be approved a year from now, he said.

More than 140 heads of states and health experts, including South African President Cyril Ramaphosa, Pakistani Prime Minister Imran Khan and Nobel laureate Joseph Stiglitz issued an appeal Thursday calling on all countries to unite behind a people's vaccine against COVID-19, to ensure any effective treatments and vaccines be available globally to anyone who needs them, for free.

At the moment, there are about a dozen vaccine candidates being tested in China, Britain, Germany and the U.S. The World Health Organization has estimated it could take about 12 to 18 months for an effective vaccine to be found. While some experts have proposed dropping the requirement for large-scale advanced clinical trials altogether, Cavaleri said that wasn't currently being considered.

Our current thinking is all vaccines under development should undergo large phase 3 trials to establish what is the level of protection, he said. But he acknowledged that could change if the situation worsened.

Things may evolve as the pandemic will evolve and we will see if we need to do something else, Cavaleri said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 14 2020 | 5:41 PM IST

Next Story